{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NEO-BLAST","nct_id":"NCT06537154","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neo-blast-nct06537154. The price is quoted from the commentary indexed so far and fixed at order. Final coverage is set when the report is built. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NEO-BLAST","arms":[{"description":"Participants found to have a clinical complete response following NAT randomized to standard of care, described as \"definitive bladder treatment\", which consists of either radical cystectomy, or chemo-radiation of the bladder","label":"cCR, Standard of care","type":"ACTIVE_COMPARATOR"},{"description":"Participants found to have a clinical complete response following NAT randomized to the investigational arm consisting of active surveillance. They will have have no local treatment to their bladder and will be monitored with cystoscopy, cytology and imaging (active surveillance)","label":"cCR, Active surveillance","type":"EXPERIMENTAL"},{"description":"Participants found to have residual urothelial carcinoma (not cCR) will received the standard of care definitive bladder treatment. They will received either radical cystectomy or chemo-radiation of the bladder.","label":"non-cCR, standard of care","type":"NO_INTERVENTION"}],"collaborators":["University of British Columbia","Canadian Institutes of Health Research (CIHR)"],"completion_date":{"date":"2030-12-31","type":"ESTIMATED"},"conditions":["Muscle-Invasive Bladder Carcinoma"],"enrollment":{"count":688,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Active Surveillance","type":"PROCEDURE"},{"name":"Control arm - Definitive bladder treatment","type":"PROCEDURE"}],"last_update":"2025-07-30","lead_sponsor":"Peter Black","official_title":"Active Surveillance Versus Definitive Local Therapy for Patients Showing Clinical Complete Response Following Neoadjuvant Therapy for Muscle Invasive Bladder Cancer","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Proportion of patients found to have a cCR and randomized on the number of patients enrolled (pilot-RCT ; phase 2)","timeFrame":"24 months"},{"measure":"Metastasis free survival at 2 years (phase 3)","timeFrame":"24 months"}],"references":[{"citation":"St-Laurent MP, Eigl BJ, Tyldesley S, Yuan R, Chang S, Vandekerkhove G, Black PC. NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol. Eur Urol Oncol. 2026 Aug 7:S2588-9311(26)00198-7. doi: 10.1016/j.euo.2026.07.008. Online ahead of print.","pmid":"42567733","type":"DERIVED"}],"start_date":{"date":"2025-07-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment","url":"https://clinicaltrials.gov/study/NCT06537154"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neo-blast-nct06537154"}